Ono Pharmaceutical Co., Ltd.

Other

University of California

National Cancer Center

Tasuku Honjo

Honjo, Tasuku

Kazuhiko Takeda

Shiro Shibayama

Takao Yoshida

Masakazu Miyamoto

Masayoshi Matsuo

Hiromu Habashita

Hiroshi Ochiai

Hideho Okada

Takaki Komiya

Tohru Kotani

Atsushi Honda

Kenichi Koda

Atsushi Oyagi

Toru Kakinuma

Masayuki Murata

Natsuko Tokuda

Noriki Watanabe

Hiroyoshi Nishikawa

Yosuke Togashi

Yukiya Ohyama

A method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing evaluation items including combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8T cells in tumor tissue or blood.

Biomarkers for determining the effectiveness of immune checkpoint inhibitors

Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2'R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1&#x2032;-cyclopropan]-2&#x2032;-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.

Method for treating brain tumors

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Substance specific to human PD-1

The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

Chemokine receptor antagonist and medical use thereof

Growing community of inventors

Mishima-gun, Japan

Kazuhiko Takeda